Tackling resistance in multidrug-resistant bacterial infections

TAXIS Pharmaceuticals is developing first-in-class anti-resistance drugs to help [...] treat patients with multidrug-resistant infections. The company is actively looking to partner its lead assets with pharma and to in-license novel anti-resistance drug candidates for development.

Like Comment
Page of
Go to the profile of TAXIS Pharmaceuticals

TAXIS Pharmaceuticals

MD, TAXIS Pharmaceuticals

TAXIS Pharmaceuticals is a clinical stage company developing first-in-class anti-resistance drugs to enable the re-use of some of the most widely prescribed generic antibiotics against antibiotic-resistant bacteria, including ESKAPE pathogens. Antimicrobial resistance is considered one of the biggest global health threats facing humanity. TAXIS’ lead asset is TXA709, an oral anti-MRSA (methicillin-resistant S. aureus) agent that recently completed a first-in-human phase 1 clinical trial with no serious adverse events. TXA709 targets the filamenting temperature-sensitive mutant Z (FtsZ) bacterial cell division protein, blocking post-mitotic septum formation. The FDA has designated TXA709 a Qualified Infectious Disease Product (QIDP). TAXIS is also developing a novel strategy consisting of targeting bacterial efflux pumps, a family of multi-protein complexes that span the bacterial cell membranes and act like bilge pumps that flush antibiotics out of the cell. Indole carboxamide efflux pump inhibitors (EPIs) represent a new drug class designed to restore the efficacy of existing antibiotics against MDR Gram-negative bacteria. They have been shown to be synergistic in vitro with 28 marketed antibiotics that no longer work. TAXIS received a CARB-X award of $3.2 million, with potential for an additional $11.4 million, to support EPI development targeting extended-spectrum β-lactamase (ESBL)-producing P. aeruginosa.

No comments yet.